New Clinical Framework Revolutionizes Risk-Guided Care for Childhood Neuroblastoma Treatment and Management

A comprehensive narrative review published in the World Journal of Pediatric Surgery introduces a unified clinical framework for treating neuroblastoma, the most common extracranial solid tumor in young children. By synthesizing evidence on molecular biology, imaging, and surgical techniques, this roadmap assists multidisciplinary teams in navigating the disease's extreme clinical variability. The framework emphasizes that successful outcomes depend on precise risk classification, integrating age, histology, and markers like MYCN amplification to tailor individual care strategies.

The research highlights that neuroblastoma management requires a departure from one-size-fits-all protocols. For low-risk infants, the study validates observation strategies that avoid unnecessary surgical or chemotherapy intervention, achieving high survival rates. Conversely, for high-risk patients, it advocates for multimodal therapy, including advanced surgery, immunotherapy, and targeted treatments. By standardizing surgical reporting and risk assessment, clinicians can better balance treatment intensity with the critical need to preserve long-term quality of life for survivors.

As survival rates for high-risk neuroblastoma remain a significant challenge, this review underscores the importance of personalized medicine and lifelong survivorship care. Beyond immediate tumor control, the authors stress the long-term impact on endocrine health, cognition, and fertility. This updated reference serves as a vital tool for surgeons and oncologists, fostering more consistent, evidence-based decision-making in clinical practice and future international research trials.